Récepteur des androgènes
Le récepteur aux androgènes (AR) est un récepteur hormonal nucléaire activé par la liaison aux androgènes, tels que la testostérone et la dihydrotestostérone. Ce récepteur joue un rôle crucial dans le développement et le maintien des caractéristiques masculines, ainsi que dans la régulation de plusieurs processus physiologiques, notamment la croissance musculaire, la libido et la densité osseuse. Les inhibiteurs du récepteur aux androgènes sont largement étudiés dans le contexte du cancer de la prostate, où la signalisation de l'AR est souvent régulée à la hausse. Chez CymitQuimica, nous offrons une gamme de modulateurs du récepteur aux androgènes de haute qualité pour soutenir vos recherches en endocrinologie, biologie du cancer et régulation hormonale.
232 produits trouvés pour "Récepteur des androgènes".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
JJH260
CAS :JJH260, a N-hydroxy hydantoin carbamate, inhibits AIG1 and ADTRP with IC50 values of 0.57 μM and 8.5 μM, respectively, and targets ABHD6, LYPLA1/2.Formule :C29H34ClN5O5Couleur et forme :SolidMasse moléculaire :568.06EPI-7170
CAS :EPI-7170: Ralaniten analogue, blocks androgen receptor, inhibits transcription in AR & variants, fights enzalutamide-resistant prostate cancer.Formule :C22H28Cl3NO6SCouleur et forme :SolidMasse moléculaire :540.88RU 59063
CAS :RU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.Formule :C17H18F3N3O2SDegré de pureté :99.09%Couleur et forme :SolidMasse moléculaire :385.4Ref: TM-T20761
1mg93,00€5mg182,00€1mL*10mM (DMSO)197,00€10mg269,00€25mg429,00€50mg610,00€100mg820,00€200mg1.071,00€Androgen receptor antagonist 13
CAS :Androgen receptor antagonist 13 (compound 8a) is an orally active androgen receptor antagonist with an IC50 of 0.20 μM. It is used in prostate cancer research.Formule :C16H15N3O3SCouleur et forme :SolidMasse moléculaire :329.37ID11916
CAS :ID11916 is an orally active compound functioning as both an androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. It disrupts androgen binding to AR, impedes nuclear translocation, and blocks androgen-dependent transcriptional activity of AR, while simultaneously elevating intracellular cGMP levels by inhibiting PKG activation. Moreover, ID11916 exhibits potent anticancer effects in prostate cancer cell lines VCaP and 22Rv1, as well as in AR-positive breast cancer cell line SK-BR-3.Formule :C29H27F3N8O3SCouleur et forme :SolidMasse moléculaire :624.637JNJ-1250132
CAS :JNJ-1250132 is a steroidal progesterone receptor modulator that inhibits binding of the receptor to DNA in vitro.Formule :C33H41NO4Couleur et forme :SolidMasse moléculaire :515.68AR antagonist 11
CAS :AR antagonist 11 (Compound c2) is a selective androgen receptor antagonist with an IC50 of 0.019 μM. It is also effective against the ARF877L/T878A mutant (IC50: 1.03 μM). Additionally, AR antagonist 11 inhibits LNCaP cell proliferation and decreases PSA protein expression (IC50: 0.54 μM). This compound is applicable in prostate cancer (PCa) research.Formule :C20H17ClN2OCouleur et forme :SolidMasse moléculaire :336.815EN1441
CAS :EN1441 is a covalent degrader that targets the androgen receptor (AR) with an EC50 value of 4.2 μM, as well as its truncated variant AR-V7. It selectively and effectively degrades AR and AR-V7 in androgen-independent prostate cancer cells. EN1441 holds potential for research into androgen-independent prostate cancer.Formule :C13H13ClN2O2Couleur et forme :SolidMasse moléculaire :264.7082-Ethylhexyl(E)-3-(4-(methoxy-D3) phenyl)acrylate
CAS :2-Ethylhexyl(E)-3-(4-(methoxy-D3) phenyl)acrylate is the deuterated form of Octinoxate. Octinoxate (Octyl methoxycinnamate) acts as an agonist of thyroid hormone receptors, leading to a reduction in triiodothyronine (T3) and thyroxine (T4) levels, as well as the transcription levels of type II deiodinase (deio2) related genes in Japanese Medaka. Commonly used as a safe ultraviolet (UV) filter in aquatic environments, Octinoxate inhibits CYP1A1 and CYP1B1, and influences hyaluronic acid (HA) metabolism in human keratinocytes through a PI3K pathway-dependent manner. It also exhibits both anti-estrogenic and anti-androgenic effects in vitro and in vivo.Formule :C18H26O3Masse moléculaire :293.42(Rac)-Idroxioleic acid sodium
CAS :(Rac)-Idroxioleic acid (2-Hydroxyoleic acid) sodium is a synthetic derivative of oleic acid (OA) that binds to the plasma membrane, altering lipid composition. This compound exhibits antitumor properties.Formule :C18H33NaO3Couleur et forme :SolidMasse moléculaire :320.44AR/BET protein degrader-1
CAS :AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.Formule :C43H44N6O5Couleur et forme :SolidMasse moléculaire :724.85ZNU-IMB-Z15
CAS :Compound Z15 (ZNU-IMB-Z15) acts as an antagonist and degrader of the androgen receptor (AR). It inhibits the proliferation of castration-resistant prostate cancer (CRPC) cell lines that are AR-positive and induces apoptosis. Compound Z15 exhibits anticancer activity both in vivo and in vitro.Formule :C20H17N3O3S2Couleur et forme :SolidMasse moléculaire :411.5VNPP433-3β
CAS :VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.Formule :C29H34N4Couleur et forme :SolidMasse moléculaire :438.61A4B17
A4B17 is an inhibitor of androgen receptor N-terminal with potential for androgen-responsive prostate cancer treatment.Formule :C14H7F4NSCouleur et forme :SolidMasse moléculaire :297.27Androgen receptor antagonist 11
CAS :Androgen receptor antagonist 11 (compound N29) is a selective, orally available antagonist.Formule :C20H19F3N4O3SCouleur et forme :SolidMasse moléculaire :452.45(+)-JJ-74-138
CAS :(+)-JJ-74-138 is a novel non-competitive androgen receptor (AR) antagonist capable of inhibiting enzalutamide-resistant castration-resistant prostate cancer (CRPC).Formule :C22H22F8N2OSCouleur et forme :SolidMasse moléculaire :514.48Androgen receptor degrader-5
CAS :Androgen receptor degrader-5 (compound 14k) demonstrates superior capabilities, specifically in androgen receptor degradation and antiproliferative activity, showcasing its promising properties.Formule :C29H25F4N5O2Couleur et forme :SolidMasse moléculaire :551.53AR ligand-44
CAS :AR ligand-44 is an androgen receptor (androgen receptor) ligand that can be utilized in the synthesis of PROTACs such as [ARD-2051].Formule :C23H24ClN3O2Couleur et forme :SolidMasse moléculaire :409.91AR antagonist 10
CAS :AR antagonist 10 (Compound Y5) is a potent, orally active androgen receptor (AR) antagonist with an IC50 value of 0.04 μM. It demonstrates a dual mechanism of action: antagonizing AR by disrupting AR dimerization and inducing AR degradation through the ubiquitin-proteasome pathway. This compound shows excellent activity against various resistant AR mutants and effectively inhibits the growth of LNCaP xenograft tumors. AR antagonist 10 is applicable for research in resistant prostate cancer.Formule :C18H17ClN4O3SCouleur et forme :SolidMasse moléculaire :404.871Androgen receptor antagonist 12
CAS :Compound EF2 (Androgen receptor antagonist 12) is an orally active antagonist of the androgen receptor (AR) with an IC50 of 0.30 µM. It inhibits the transcriptional activity of mutant AR and the proliferation of AR-positive PCa (prostate cancer) cell lines. Additionally, Compound EF2 blocks the nuclear translocation of AR and suppresses tumor growth in the C4-2B xenograft mouse model. This compound is used for research in prostate cancer.Formule :C12H8F3N3O2Couleur et forme :SolidMasse moléculaire :283.21
